Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia ; volume:14 ; number:1 ; day:29 ; month:7 ; year:2021 ; pages:1-4 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (29.7.2021), 1-4, 12.2021
- Urheber
-
Pimpinelli, Fulvia
Marchesi, Francesco
Piaggio, Giulia
Giannarelli, Diana
Papa, Elena
Falcucci, Paolo
Spadea, Antonio
Pontone, Martina
Di Martino, Simona
Laquintana, Valentina
La Malfa, Antonia
Di Domenico, Enea Gino
Di Bella, Ornella
Falzone, Gianluca
Ensoli, Fabrizio
Vujovic, Branka
Morrone, Aldo
Ciliberto, Gennaro
Mengarelli, Andrea
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01130-1
- URN
-
urn:nbn:de:101:1-2021102620211690296576
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pimpinelli, Fulvia
- Marchesi, Francesco
- Piaggio, Giulia
- Giannarelli, Diana
- Papa, Elena
- Falcucci, Paolo
- Spadea, Antonio
- Pontone, Martina
- Di Martino, Simona
- Laquintana, Valentina
- La Malfa, Antonia
- Di Domenico, Enea Gino
- Di Bella, Ornella
- Falzone, Gianluca
- Ensoli, Fabrizio
- Vujovic, Branka
- Morrone, Aldo
- Ciliberto, Gennaro
- Mengarelli, Andrea
- SpringerLink (Online service)
Ähnliche Objekte (12)
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Myeloproliferative disorders : current perspectives on diagnostic criteria, histopathology and treatment in essential thrombocythemia, polycythemia rubra vera and chronic idiopathic myelofibrosis
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
Polycythemia vera and essential thombocythemia - A single institution experience
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
Myelofibrosis
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Myeloproliferative disorders : current perspectives on diagnostic criteria, histopathology and treatment in essential thrombocythemia, polycythemia rubra vera and chronic idiopathic myelofibrosis
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
Polycythemia vera and essential thombocythemia - A single institution experience
Emerging agents and regimens for polycythemia vera and essential thrombocythemia
Myelofibrosis
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Myeloproliferative disorders : current perspectives on diagnostic criteria, histopathology and treatment in essential thrombocythemia, polycythemia rubra vera and chronic idiopathic myelofibrosis
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
Polycythemia vera and essential thombocythemia - A single institution experience
Emerging agents and regimens for polycythemia vera and essential thrombocythemia